www s

PubMedCrossRef 12. Borysowski J, Weber-Dabrowska B, Gorski A: Bacteriophage endolysins as a novel class of antibacterial agents. selleck chemical Exp Biol Med (Maywood) 2006,231(4):366–377. 13. Loessner MJ: Bacteriophage endolysins–current state of research and applications. Curr Opin Microbiol 2005,8(4):480–487.PubMedCrossRef 14. Hermoso JA, Garcia JL, Garcia P: Taking

aim on bacterial pathogens: from phage therapy to enzybiotics. Curr Opin Microbiol 2007,10(5):461–472.PubMedCrossRef 15. De Groot AS, Scott DW: Immunogenicity of protein therapeutics. Trends Immunol 2007,28(11):482–490.PubMedCrossRef 16. Wishart DS: Bioinformatics in drug development and assessment. Drug Metab Rev 2005,37(2):279–310.PubMed 17. Wu H, Lu H, Huang J, Li G, Huang Q: EnzyBase: a novel database for enzybiotic studies. BMC Microbiol 2012, 12:54.PubMedCrossRef 18. Magrane M, Consortium U: UniProt Knowledgebase: a hub of integrated protein data. Oxford: Database; 2011. 2011:bar009 19. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, Pang N, Forslund K, Ceric G, Clements J: The Pfam protein families database. Nucleic Acids Res 2012,40(Database issue):290–301.CrossRef 20. Scheer M, Grote A, Chang A, Schomburg I, Munaretto C, Rother M, Sohngen C, Stelzer M, Thiele J, Schomburg D: BRENDA, the enzyme information system in 2011. Nucleic Acids Res 2011,39(Database issue):670–676.CrossRef Ruboxistaurin 21. Finn RD, Clements J, Eddy

SR: HMMER web server: interactive sequence similarity searching. Nucleic Acids Res 2011,39(Web Server issue):29–37.CrossRef Competing interests All authors declare that they have no competing interest. Authors’ contributions KH carried out acquisition of data for phiBIOTICS database and scoring of phiBiScan statistical evaluation, participated in conception and design of the study and drafted the manuscript. MS carried out data analysis, constructed phiBiScan utility and participated in drafting and final approval of manuscript. LK conceived of the study, participated in its design and coordination and participated in Silibinin drafting

and final approval of manuscript. All authors read and approved the final manuscript.”
“Background Cholera is an acute diarrhoeal disease caused by toxigenic Vibrio cholerae. The two most important serogroups are O1 and O139, which can cause periodic Lazertinib order outbreaks reaching epidemic or pandemic proportions [1]. However, non-O1/non-O139 serogroups have been linked with cholera-like-illness sporadically [2–6]. Symptoms may range from mild gastroenteritis to violent diarrhoea, similar to those elicited by the O1 toxigenic strains [7]. However, patients generally suffer a less severe form of the disease than those infected by O1 toxigenic strains [8–10]. Non-O1/non-O139 V. cholerae strains have also caused localised outbreaks in many countries, including India and Thailand [3, 11–15]. More recently, an O75 V. cholerae outbreak associated with the consumption of oysters was reported in the USA [5, 6]. Non-O1/non-O139 V.

No related posts.

Comments are closed.